The estimated Net Worth of Mark S. Blumenkranz is at least $586 Thousand dollars as of 11 May 2023. Mark Blumenkranz owns over 14,588 units of 1Life Healthcare stock worth over $528,489 and over the last 9 years he sold ONEM stock worth over $0. In addition, he makes $57,099 as Independent Director at 1Life Healthcare.
Sign up
Mark Blumenkranz ONEM stock SEC Form 4 insiders trading
Mark has made over 5 trades of the 1Life Healthcare stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 14,588 units of ONEM stock worth $240,264 on 11 May 2023.
The largest trade he's ever made was exercising 14,588 units of 1Life Healthcare stock on 11 May 2023 worth over $240,264. On average, Mark trades about 2,035 units every 37 days since 2015. As of 11 May 2023 he still owns at least 32,088 units of 1Life Healthcare stock.
You can see the complete history of Mark Blumenkranz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Blumenkranz biography
Dr. Mark S. Blumenkranz M.D. serves as Independent Director of the Company. Since October 2015, Dr. Blumenkranz has served as the managing director of Lagunita Biosciences LLC, a healthcare investment company. Since September 2019, Dr. Blumenkranz has served as the chief executive officer of Kedalion Therapeutics Inc., an ophthalmic drug development company. From 1997 to August 2015, he served as the H.J. Smead Professor and Chairman of the Department of Ophthalmology at Stanford University School of Medicine and as the inaugural director of the Byers Eye Institute, a nationally-recognized eye care center. From January 2015 to August 2015, Dr. Blumenkranz served on the board of directors of Presbia PLC, a medical device company. From July 2006 to February 2017, Dr. Blumenkranz served on the board of directors of Adverum Biotechnologies Inc., a biotechnology company. He also serves on the board of directors of several private biotechnology and medical device companies. Dr. Blumenkranz earned an A.B. in Biology, an M.M.S. in Biochemical Pharmacology and an M.D. from Brown University. He received his surgical internship and ophthalmology residency training at the Stanford University School of Medicine and his fellowship training in vitreoretinal surgery at the Bascom Palmer Eye Institute at the University of Miami School of Medicine. Blumenkranz is qualified to serve as a member of our board of directors because of his experience as a director and founder of several biotechnology companies as well as his significant expertise in medical practice.
What is the salary of Mark Blumenkranz?
As the Independent Director of 1Life Healthcare, the total compensation of Mark Blumenkranz at 1Life Healthcare is $57,099. There are 8 executives at 1Life Healthcare getting paid more, with Amir Rubin having the highest compensation of $13,920,200.
How old is Mark Blumenkranz?
Mark Blumenkranz is 68, he's been the Independent Director of 1Life Healthcare since 2019. There are no older and 16 younger executives at 1Life Healthcare.
What's Mark Blumenkranz's mailing address?
Mark's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.
Insiders trading at 1Life Healthcare
Over the last 5 years, insiders at 1Life Healthcare have traded over $573,693,882 worth of 1Life Healthcare stock. The most active insiders traders include Group Management L.L.C.Carl..., Amir Dan Rubin, and Scott C Taylor. On average, 1Life Healthcare executives and independent directors trade stock every 10 days with the average trade being worth of $4,338,939. The most recent stock trade was executed by Bjorn B Thaler on 15 February 2023, trading 13,829 units of ONEM stock currently worth $227,764.
What does 1Life Healthcare do?
1Life Healthcare, Inc. operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as third-party sponsorship. Its membership model includes seamless access to 24/7 digital health services paired with inviting in-office care routinely covered under health insurance programs. The company also offers administrative and managerial services pursuant to contracts with physician-owned professional corporations or One Medical Entities. As of December 31, 2021, it had 703,000 consumer and enterprise members, and 33,000 At-Risk members; 182 medical offices in 25 markets; and 8,500 enterprise clients in the United States. The company was incorporated in 2002 and is headquartered in San Francisco, California.
What does 1Life Healthcare's logo look like?
Complete history of Mark Blumenkranz stock trades at Kala Bio, IVERIC bio Inc, and 1Life Healthcare
1Life Healthcare executives and stock owners
1Life Healthcare executives and other stock owners filed with the SEC include:
-
Amir Rubin,
Chairman of the Board, President, Chief Executive Officer -
Bjorn Thaler,
Chief Financial Officer -
Kimber Lockhart,
Chief Technology Officer -
Amir Dan Rubin MBA,
Chair, CEO & Pres -
Bjorn B. Thaler,
Chief Financial Officer -
Kalen Holmes,
Independent Director -
Paul Auvil,
Independent Director -
David Kennedy,
Independent Director -
Freda Lewis-Hall,
Independent Director -
Mark Blumenkranz,
Independent Director -
David Singer,
Independent Director -
Robert Schmid,
Independent Director -
Bruce Dunlevie,
Lead Independent Director -
Andrew Diamond,
Chief Medical Officer -
Lisa Mango,
General Counsel and Corporate Secretary -
Jenni Vargas,
Chief Strategy Officer -
Rajneesh Behal M.D., MPH,
Chief Quality Officer -
Dr. Andrew S. Diamond M.D., Ph.D.,
Chief Medical Officer -
Christine Morehead,
Chief People Officer -
Doug Sweeny,
Chief Marketing Officer -
Lisa A. Mango,
Gen. Counsel & Corp. Sec. -
Ken Goff,
VP of Investor Relations -
Stuart Parmenter,
Chief Technology Officer -
Scott C Taylor,
-
Vikas Agarwal,
Chief Accounting Officer -
Morgan Investment Managemen...,
10% owner -
Investment Partners Xii L P...,
10% owner -
Digital Growth Fund Ii L.P....,
10% owner -
Group Management L.L.C.Carl...,
-
Capital Management Co. V, L...,
-
Mary Ann Tocio,